[{"orgOrder":0,"company":"Kashiv Specialty Pharmaceuticals","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"K102","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Kashiv Specialty Pharmaceuticals","amount2":0.11,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0.11,"dosageForm":"","sponsorNew":"Kashiv Specialty Pharmaceuticals \/ Amneal","highestDevelopmentStatusID":"1","companyTruncated":"Kashiv Specialty Pharmaceuticals \/ Amneal"},{"orgOrder":0,"company":"Kashiv Specialty Pharmaceuticals","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Filgrastim","moa":"GCSF","graph1":"Oncology","graph2":"Phase III","graph3":"Kashiv Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kashiv Specialty Pharmaceuticals \/ Amneal","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv Specialty Pharmaceuticals \/ Amneal"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Filgrastim","moa":"GCSF","graph1":"Oncology","graph2":"Approved","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kashiv BioSciences \/ Kashiv Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Kashiv BioSciences \/ Kashiv Biosciences"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"Hematopoietic Cell","graph1":"Hematology","graph2":"Approved","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kashiv BioSciences \/ Kashiv Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Kashiv BioSciences \/ Kashiv Biosciences"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Brand Institute","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kashiv BioSciences \/ Brand Institute","highestDevelopmentStatusID":"12","companyTruncated":"Kashiv BioSciences \/ Brand Institute"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kashiv BioSciences \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Kashiv BioSciences \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Pegfilgrastim-pbbk","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kashiv BioSciences \/ Kashiv Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Kashiv BioSciences \/ Kashiv Biosciences"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Kashiv BioSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Kashiv BioSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Omalizumab","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kashiv BioSciences \/ Alvotech","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Alvotech"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Omalizumab","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Kashiv BioSciences \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kashiv BioSciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kashiv BioSciences \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Kashiv BioSciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : ADL018 (omalizumab) a biosimilar candidate to Xolair is being evaluated in late-stage clinical trial studies for the treatment of chronic idiopathic urticaria.

                          Brand Name : ADL018

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 25, 2024

                          Lead Product(s) : Omalizumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Through the license agreement, Amneal will commercialize ADL018 (omalizumab) in the US. It is being evaluated in late-stage clinical trial studies for the treatment of chronic idiopathic urticaria.

                          Brand Name : ADL018

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 01, 2024

                          Lead Product(s) : Omalizumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Amneal Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the agreement, Alvotech will receive an exclusive license to commercialize AVT23 (also called ADL018), a proposed biosimilar to Xolair (omalizumab), which will be developed and manufactured by Kashiv.

                          Brand Name : AVT23

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 03, 2023

                          Lead Product(s) : Omalizumab

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Alvotech

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : ADL018 (omalizumab) is a monoclonal antibody that inhibits the binding of IgE to the high-affinity IgE receptor on the surface of mast cells and basophils. It is being developed as a biosimilar candidate to XOLAIR® approved to treat chronic spontaneous ...

                          Brand Name : ADL018

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 02, 2023

                          Lead Product(s) : Omalizumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : ADL018 (omalizumab) is a monoclonal antibody that inhibits the binding of IgE to the high-affinity IgE receptor on the surface of mast cells and basophils. It is being developed as a biosimilar candidate to XOLAIR® approved to treat chronic spontaneous ...

                          Brand Name : ADL018

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 05, 2023

                          Lead Product(s) : Omalizumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Fylnetra (pegfilgrastim-pbbk) is a leukocyte growth factor which decreases the incidence of infection, indicated for patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of...

                          Brand Name : Fylnetra

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 16, 2023

                          Lead Product(s) : Pegfilgrastim-pbbk

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved

                          Recipient : Amneal Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : FYLNETRA® (pegfilgrastim-pbbk), used to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence ...

                          Brand Name : Fylnetra

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 21, 2022

                          Lead Product(s) : Pegfilgrastim

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved

                          Sponsor : Brand Institute

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : FYLNETRA (Pegfilgrastim-pbbk) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.

                          Brand Name : Fylnetra

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 31, 2022

                          Lead Product(s) : Pegfilgrastim

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved

                          Sponsor : Amneal Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : FYLNETRA (pegfilgrastim), is used to treat neutropenia (low neutrophils which are a type of white blood cells that fight infection) which is commonly experienced by patients undergoing chemotherapy.

                          Brand Name : Fylnetra

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 27, 2022

                          Lead Product(s) : Pegfilgrastim

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved

                          Recipient : Amneal Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : U.S. FDA approved biologics license application for RELEUKO (filgrastim-ayow), a biosimilar referencing Neupogen, to treat neutropenia which is commonly experienced by patients undergoing chemotherapy, acute myeloid leukemia and nonmyeloid malignancies.

                          Brand Name : Releuko

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          March 01, 2022

                          Lead Product(s) : Filgrastim

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Recipient : Amneal Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank